Yissum - Research Development Company of the Hebrew University

Novel Macrocyclic Molecules for Treating and Preventing HIV Infection (CG1)

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Novel Macrocyclic Molecules for Treating and Preventing HIV Infection (CG1)
Project ID : 7-2008-2156

Description of the technology

New compounds mimicking CD4 protein, inhibiting gp120/CD4 interaction and the consequent infection of cells by HIV

Categories

HIV/AIDS, Therapeutic Drug, Preventive Treatment

Patent Status

US patent application filed

Target Market

In 2007, HIV drugs achieved global sales of more than 9 billion dollars. Leading drugs capture more than 1 billion dollars in annual sales.

The Field

  • HIV infects immune cells by the direct interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule expressed on the target cells. After infection, immune cells are gradually destroyed, which leads to the inevitable lost of cell-mediated immunity and to an increased susceptibility to opportunistic infections.
  • Backbone cyclization (BC) is a tool developed to impose conformational constraints on peptides by interconnecting its backbone atoms. This approach allows connecting discontinuous active residues in various conformations. Some of these conformations are similar to the arrangement of residues that constitutes the active sites of natural proteins.
  • Cycloscan is a selection method in which libraries of BC are screened to discover the most active BC peptides.

Innovation Highligts

  • A series of new compounds mimicking CD4 protein, discovered by the BC-Cycloscan platform, that inhibit gp120/CD4 interaction and the consequent infection of cells by HIV.
  • The new compounds show high intestinal permeability and are metabolically stable, which makes them potential orally-deliverable drugs.

Development Milestones

  • A series of macrocyclic molecules mimicking the CD4 structure were synthesized. Some of these molecules successfully inhibited viral penetration into cultured T-cells by inhibiting gp120/CD4 interaction. Additionally, the molecules showed high intestinal permeability in in-vitro and ex-vivo models, and were stable to intestinal enzymes.

The Opportunity

  • An estimated 33.2 million people live with AIDS worldwide. Currently available anti-retroviral therapies often fail to alleviate patient’s symptoms, are very slow clearing the infection, and frequently induce the development HIV-1 strains resistant to the treatment. Nowadays, as much as fifty percent of medicated patients have no benefit from their treatment.

Project manager

Ariela Markel
VP, Business Development, Healthcare

Project researchers

Chaim Gilon
HUJI, Faculty of Science
The Institute of Chemistry

Amnon Hoffman
HUJI, School of Pharmacy
Pharmaceutics

Moshe Kotler
HUJI, Faculty of Medicine
Pathology

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • infectious diseases
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.